Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ER positive, HER2-positive, PR positive status confers therapeutic sensitivity to Neratinib in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved neratinib for reimbursement as a treatment option for the extended adjuvant treatment of adults with early-stage hormone-receptor positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.
This statement is based on a regulatory approval from the Health Service Executive:
Extended adjuvant treatment of adults with early-stage hormone receptor-positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.